Table 1:
Donor, recipient, and transplant characteristics
| Deceased Donor Characteristics | (N=1298) | Recipient and transplant characteristics | (N=2430) | ||
|---|---|---|---|---|---|
| Age, years | 41 ± 15 | Age, years | 53 ± 15 | ||
| Male | 784 (60%) | Male | 1492 (61%) | ||
| Black race | 205 (16%) | Black race | 956 (39%) | ||
| Hispanic ethnicity | 171 (13%) | Hispanic ethnicity | 279 (11%) | ||
| BMI, kg/m2 | 28 ± 7 | BMI, kg/m2 | 28.0 ± 5.8 | ||
| Hypertension | 399 (31%) | Cause ESRD | Diabetes | 726 (30%) | |
| Diabetes | 130 (10%) | Hypertension | 643 (26%) | ||
| Cause of death | Head trauma | 396 (31%) | Glomerulonephritis | 391 (16%) | |
| Anoxia | 425 (34%) | Graft failure | 174 (7%) | ||
| Stroke | 427 (34%) | Other or unknown | 496 (20%) | ||
| Other | 18 (1%) | Preemptive transplant | 274 (11%) | ||
| Hepatitis C seropositive | 48 (4%) | Dialysis duration, months | 46 ± 38 | ||
| ECD | 246 (19%) | Previous kidney transplant | 315 (13%) | ||
| DCD | 206 (16%) | Pre-transplant blood transfusion | 438 (18%) | ||
| KDRI | 1.29 ± 0.41 | PRA | Continuous, % | 21 ± 35 | |
| KDPI, % | 48 ± 27 | 0% | 1545 (64%) | ||
| Admission to procurement, days | 5 ± 7 | 1–20% | 178 (7%) | ||
| Admission SCr, mg/dL | 1.10 ± 0.61 | 21–80% | 326 (13%) | ||
| Terminal SCr, mg/dL | 1.17 ± 0.85 | >80% | 381 (16%) | ||
| Urine creatinine, mg/dL | 49.09 ± 48.41 | Cold ischemia time, hours | 15.3 ± 7.1 | ||
| Number of individual kidneys transplanted | 1 | 166 (13%) | HLA Mismatch | Continuous | 4.2 ± 1.5 |
| 2 | 1132 (87%) | 0 | 153 (6%) | ||
| Donor AKI stage | No AKI | 976 (75%) | 1 | 21 (1%) | |
| Stage 1 | 211 (16%) | 2 | 82 (3%) | ||
| Stage 2 | 62 (5%) | 3 | 292 (12%) | ||
| Stage 3 | 49 (4%) | 4 | 642 (26%) | ||
| 5 | 820 (34%) | ||||
| 6 | 414 (17%) | ||||
Values are mean (SD) or n (%). ECD, expanded-criteria donor; DCD, donation after cardiovascular determination of death; KDRI, kidney donor risk index; KDPI, kidney donor profile index; SCr serum creatinine; eGFR, estimated glomerular filtration rate; ESRD, end-stage renal disease; PRA; panel reactive antibody; HLA, human leukocyte antigen.